Latest Headlines

Latest Headlines

With Opsumit launch rolling, Actelion doesn't 'need' M&A: CEO

Back in 2013, Actelion launched Opsumit, a new-and-improved pulmonary arterial hypertension drug it hoped would help make up sales for its aging Tracleer. And so far, everything is going according to plan.

Actelion says it doesn't need big buyouts as billion-dollar rumors simmer

Fast-growing biotech Actelion said it's not desperate for a big deal but hasn't ruled out its reported $2.5 billion effort to snatch up the smaller ZS Pharma.

Actelion confirms $2.5B offer for ZS Pharma

Swiss biotech Actelion is discussing a $2.5 billion buyout of ZS Pharma, it confirmed Thursday, sending shares of its target soaring.

UPDATED: ZS Pharma rockets up on word of a $2.5B offer from Actelion

ZS Pharma, awaiting FDA approval for a kidney drug, saw its share value soar about 30% after Actelion confirmed that it's discussing a multibillion-dollar buyout with the company.

Japan's MHLW gives nods for Remicade, VFend, Tracleer, INOflo new indications

Japan's Ministry of Health, Labor and Welfare last week gave the nod to several new drug indications, including Mitsubishi Tanabe's Remicade for intravenous use and indications of entero-Behcet, neuro-Behcet and vasculo-Behcet diseases when existing treatments are inadequate, a spokesman for the ministry said.

Japan's PAFSC to review application from Takeda on glatiramer this week

Japan's Pharmaceutical Affairs and Food Sanitation Council's First Committee will review Takeda Pharmaceutical's glatiramer acetate drug approval application for relapsing multiple sclerosis on Aug. 28, a Ministry of Health, Labor and Welfare spokesman said.

Actelion taps DKSH to break into Asia

Market-access contractor DKSH has signed a deal with Actelion Pharmaceuticals to help the company bolster its position in Asia.

Actelion's Opsumit growth heralds smooth switch off aging Tracleer

Actelion has been prepping its new pulmonary arterial hypertension drug Opsumit to pick up the slack once the aging Tracleer goes off patent in November. And Opsumit seems poised for the job, raking in promising second-quarter numbers and prompting the company to boost its full-year guidance.

Actelion pours out $33M to create vaccine startup with Max Planck Society

Switzerland-based Actelion is jumping into the vaccines industry by creating Vaxxilon, a startup that will focus on synthetic carbohydrate vaccines. It has licensed exclusive rights to multiple preclinical vaccines and other technologies from the Max Planck Society and will invest up to €30 million ($33 million), which will come in tranches over three to four years.

Actelion creates vaccine startup with €30M investment and Max Planck assets

Actelion has got into startup creation. The Swiss biotech has committed €30 million ($33 million) to set up Vaxxilon, a synthetic carbohydrate vaccine-focused startup with a mission to push a program licensed from the Max Planck Society into the clinic within the next three years.